The proposed postdoctoral training program, Cancer-Translational Nanotechnology Training (Cancer-TNT) Program, is a diverse and synergistic 3-year training program bringing together 25 faculty and 9 Departments from three schools to train the next generation of interdisciplinary leaders who will pursue challenges in cancer research and clinical translation. Cancer nanotechnology is a rapidly growing field that requires close interactions of researchers from disparate fields of science, such as chemistry, materials science, cancer biology, and medicine. During the proposed 5-year cycle, we will recruit a total of 12 postdoctoral trainees to provide them with education and cross-disciplinary training to develop interdisciplinary researchers in cancer nanotechnology translation. Eight (8) trainees will complete training during the 5-year cycle. Our trainees' skill sets will bridge multiple disciplines such as chemistry, molecular biology, bioengineering, molecular imaging, nanoengineering, and clinical cancer medicine. Trainees will be able to advance cancer research, diagnosis, and management. The Molecular Imaging Program at Stanford (MIPS) from the medicine side, with the Departments of Chemistry, Materials Science and Engineering from the engineering side, will provide a solid foundation for our program. The Stanford environment also leads a productive Center for Cancer Nanotechnology Excellence (CCNE-T), an NCI Designated Comprehensive Cancer Center, an In Vivo Cellular and Molecular Imaging Center (ICMIC @ Stanford), the highly effective interdisciplinary Bio-X program, facilities for Nanofabrication and Nanocharacterization, as well as Nanoinformatics capabilities, the Canary Center for Cancer Early Detection, and a Physical Sciences Oncology Center (PSOC), in which several of our mentors have leading roles. Through these activities, we have already been successfully training the next generation of cancer nanotechnologists and we are excited by the possibility to formalize and expand training activities through the Cancer-TNT. Our program includes a diverse group of faculty mentors representing five program areas. Through this mentor group, we are able to bring together formal courses in cancer biology, cancer immunology, molecular imaging, molecular pharmacology, and gene therapy, nanomedicine, micro/nanofabrication, biochips, electrical engineering, and materials science; hands-on training activities in Nanocharacterization; and a clinical component including Stanford Oncology Clinical Lecture Series. The Cancer-TNT fellows will be recruited into a 3-year program to complete coursework and research with two complementary mentors. Trainees will prepare a mock grant proposal in their second year to help them gain experience and confidence in the grant application process. A Training Committee will oversee trainee progress, with an Advisory Committee monitoring the entire program. Stanford University, with support from the NCI, is poised to be a major training center for the rapidly growing field of cancer nanotechnology.

Public Health Relevance

Nanotechnology promises great benefits that will improve how we detect, treat and monitor cancer. To achieve this vision, a new generation of scientists with the skills and educational backgrounds from both engineering, chemistry, materials science, cancer biology and medicine are needed. The Stanford University proposed Cancer-Translational Nanotechnology Training (Cancer-TNT) Program provides the opportunity for talented scientists to learn the intricacies of merging nanotechnology with the biological/medical sciences, especially for use in cancer, and to become leaders for the rapidly growing field of cancer nanotechnology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee F - Institutional Training and Education (NCI-F)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Schools of Medicine
United States
Zip Code
Pratt, Edwin C; Shaffer, Travis M; Zhang, Qize et al. (2018) Nanoparticles as multimodal photon transducers of ionizing radiation. Nat Nanotechnol 13:418-426
Haabeth, Ole A W; Blake, Timothy R; McKinlay, Colin J et al. (2018) mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A 115:E9153-E9161
Gouw, Arvin M; Eberlin, Livia S; Margulis, Katherine et al. (2017) Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A 114:4300-4305
Altman, Brian J; Hsieh, Annie L; Gouw, Arvin M et al. (2017) Correspondence: Oncogenic MYC persistently upregulates the molecular clock component REV-ERB?. Nat Commun 8:14862
Casey, Stephanie C; Tong, Ling; Li, Yulin et al. (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:227-31
Gouw, Arvin M; Toal, Georgia G; Felsher, Dean W (2016) Metabolic vulnerabilities of MYC-induced cancer. Oncotarget 7:29879-80
Shroff, Emelyn H; Eberlin, Livia S; Dang, Vanessa M et al. (2015) MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A 112:6539-44
Yetil, Alper; Anchang, Benedict; Gouw, Arvin M et al. (2015) p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget 6:3563-77
Eberlin, Livia S; Gabay, Meital; Fan, Alice C et al. (2014) Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc Natl Acad Sci U S A 111:10450-5